List of Excipients in Branded Drug LUCENTIS

« Back to Dashboard

Lucentis Excipient Strategy and Commercial Opportunities in Ranibizumab

Last updated: September 29, 2026

Lucentis is a ranibizumab ophthalmic biologic whose commercial value has shifted from molecule-level exclusivity to formulation execution, delivery devices, biosimilar manufacturing, and retinal-care economics. Its core formulation uses trehalose, histidine, histidine hydrochloride, polysorbate 20, and water for injection. The main commercial opportunities are biosimilar ranibizumab, ready-to-use presentations, prefilled syringes, low-waste packaging, sustained delivery, and manufacturing improvements that preserve aggregation and particulate controls.

What is the Lucentis formulation and which excipients does it contain?

Lucentis is a sterile, preservative-free solution of ranibizumab for intravitreal injection. The U.S. product is supplied as a 10 mg/mL solution in a single-dose vial and as a 10 mg/mL single-dose prefilled syringe. The recommended 0.05 mL dose contains 0.5 mg of ranibizumab for most approved indications. A 0.03 mL dose is used for certain pediatric indications and for some disease-specific regimens.[1]

Formulation component	Function in Lucentis
Ranibizumab	Anti-VEGF-A Fab therapeutic
Alpha,alpha-trehalose dihydrate	Stabilizer and tonicity contributor
Histidine	Buffer
Histidine hydrochloride monohydrate	Buffer and pH-control component
Polysorbate 20	Surfactant that limits interfacial aggregation
Water for injection	Vehicle
pH	Approximately 5.5
Concentration	10 mg/mL
Preservatives	None

The excipient design is conventional for a protein ophthalmic injection. Trehalose supports conformational stability during storage and freezing or drying stress. Histidine provides buffering at mildly acidic pH. Polysorbate 20 reduces adsorption and agitation-induced aggregation at liquid-air and container surfaces. The formulation has to balance protein stability against ocular tolerability, visible and subvisible particles, silicone-oil exposure, container compatibility, and injection-device performance.

Why is trehalose important in ranibizumab formulations?

Trehalose is the principal stabilizing excipient in the Lucentis liquid formulation. It can protect the antibody fragment during thermal, freeze-thaw, and interfacial stress. For a sterile intravitreal product, the commercial advantage is not simply protein shelf life. The excipient must support a low-particle formulation that remains compatible with vial stoppers, syringes, needles, and shipping conditions.

Trehalose also contributes to osmolality. Its level therefore affects both protein stability and ocular tolerability. A biosimilar developer cannot treat trehalose as an interchangeable formulation ingredient without evaluating:

• aggregation and fragmentation;
• potency and VEGF-binding activity;
• subvisible particle counts;
• viscosity and delivered volume;
• container-closure extractables and leachables;
• freeze-thaw behavior;
• adsorption to syringe and needle surfaces;
• compatibility with silicone oil;
• in-use stability after dose withdrawal.

The commercial opportunity is strongest where a developer can retain the reference product's functional stability while reducing manufacturing complexity or improving device delivery.

What role do histidine and polysorbate 20 play?

Histidine and histidine hydrochloride establish the buffer system. The approximately pH 5.5 environment supports ranibizumab stability while maintaining intravitreal tolerability. Changes to buffer species, concentration, or pH can affect charge variants, aggregation, adsorption, and biological activity.

Polysorbate 20 is used at a low concentration to control surface-induced aggregation. It is also a significant product-quality variable. Polysorbate degradation can generate free fatty acids and particulates, while oxidation can affect protein quality and impurity profiles. A biosimilar or reformulated product therefore requires control of:

1. polysorbate identity and concentration;
2. peroxide and degradation-product levels;
3. mixing and hold-time conditions;
4. contact with air-liquid interfaces;
5. filtration and filling stresses;
6. storage temperature and excursion limits.

A formulation that replaces polysorbate 20 with polysorbate 80, poloxamer, or another surfactant may create a patent and commercial position, but it also creates a larger comparability burden. Such a product would not automatically qualify as a formulation-neutral biosimilar.

What patents protect Lucentis and its formulation?

Lucentis is a biologic, so U.S. exclusivity analysis differs from the small-molecule Orange Book model. Biologic patents may cover the ranibizumab sequence, anti-VEGF binding characteristics, production methods, formulations, dosing regimens, delivery devices, and manufacturing controls. FDA lists biologics and their reference-product information through the Purple Book rather than the Orange Book.[2]

The central U.S. composition-of-matter and formulation patent terms for the original Lucentis program have largely expired or reached the end of their principal commercial life. Commercial protection now depends more heavily on:

• later-filed formulation patents;
• prefilled-syringe and container patents;
• sustained-delivery systems;
• method-of-use patents;
• manufacturing and purification claims;
• contractual arrangements governing biosimilar commercialization;
• regulatory exclusivity and litigation settlements.

The original Lucentis approval was issued in 2006. The product did not retain an active small-molecule-style Orange Book patent-blocking structure. The practical U.S. competition issue is biosimilar interchangeability, market contracting, physician adoption, and payer preference rather than a single Orange Book-listed patent expiration date.[1,2]

What is the FDA and Purple Book status of Lucentis?

Lucentis is FDA-approved for several retinal vascular and neovascular ophthalmic indications, including neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. The label has changed over time as indications, dosing schedules, and presentations evolved.[1]

Regulatory item	Status
Active ingredient	Ranibizumab
Reference product	Lucentis
Sponsor in the U.S.	Genentech
Global commercial relationship	Roche and Novartis
FDA product type	Licensed biologic
Orange Book status	Not the primary biologic reference
Purple Book status	Reference product listed with ranibizumab biosimilar products
Original U.S. approval	2006
Delivery forms	Single-dose vial and prefilled syringe
Preservative	None

The Purple Book lists biosimilar competition for ranibizumab. FDA approved Byooviz, ranibizumab-nuna, in 2021, and Cimerli, ranibizumab-eqrn, in 2022.[3,4] These products established the regulatory pathway for follow-on ranibizumab in the United States.

Which companies are challenging Lucentis commercially?

The principal U.S. competitors are Samsung Bioepis and Coherus BioSciences.

Product	Sponsor or commercial company	FDA approval	Relationship to Lucentis
Byooviz, ranibizumab-nuna	Samsung Bioepis	2021	Biosimilar to Lucentis
Cimerli, ranibizumab-eqrn	Coherus BioSciences	2022	Biosimilar to Lucentis
Ranibizumab biosimilars outside the U.S.	Multiple regional manufacturers	Varies by jurisdiction	Competition depends on local approval and patent rules

Byooviz entered the market under Samsung Bioepis' biosimilar strategy and a commercialization relationship with Biogen. Cimerli was commercialized by Coherus, which positioned the product around broad interchangeability and contracting flexibility.[5,6]

The competitive threat is not limited to identical excipient formulas. Biosimilars compete through:

• lower acquisition cost;
• payer contracts;
• physician office economics;
• reduced wastage;
• prefilled-syringe availability;
• supply reliability;
• purchasing-group discounts;
• interchangeability status where applicable.

What formulation patents could create new commercial value?

The strongest formulation opportunities are usually not broad claims to trehalose, histidine, or polysorbate 20 alone. Those ingredients are widely used in biologics. More defensible claims may combine the excipients with measurable product attributes or a specific presentation.

Potential claim categories include:

Low-particle ranibizumab formulations

Claims can focus on particle limits after agitation, shipping, freeze-thaw exposure, or storage. These claims are commercially relevant because intravitreal products have strict quality expectations and are exposed to handling through specialty pharmacies, hospitals, and retina clinics.

Surfactant-stabilized prefilled syringes

A prefilled syringe patent may combine ranibizumab, polysorbate, syringe materials, silicone-oil controls, a specific needle, and a defined delivered volume. Device and formulation claims can create practical barriers even when the active ingredient is no longer strongly protected.

Extended shelf-life formulations

A product with reduced aggregation, lower oxidation, or improved stability under temperature excursions could reduce inventory losses. The commercial value depends on whether the improvement supports a meaningful regulatory label or supply-chain advantage.

Reduced-volume presentations

The product is administered in very small volumes. A presentation that reduces overfill, dead volume, or preparation waste can produce savings across high-volume retina practices. Any reduced-volume product must demonstrate accurate dose delivery and equivalent clinical exposure.

Alternative surfactant systems

Poloxamers, phospholipid systems, and modified polysorbates could support patentable differentiation. The main risk is that a new surfactant may introduce a higher immunogenicity, particulate, extractables, or comparability burden.

How does Lucentis compare with Eylea and Vabysmo?

Lucentis competes with other anti-VEGF products rather than with biosimilars alone. Eylea, aflibercept, and Vabysmo, faricimab-svoa, compete on dosing interval, clinical positioning, reimbursement, and administration burden.

Product	Active ingredient	Primary commercial distinction	Excipient strategy
Lucentis	Ranibizumab	Established anti-VEGF Fab; vial and prefilled syringe	Trehalose, histidine system, polysorbate 20
Eylea	Aflibercept	Broad retinal use and extended-interval dosing	Distinct recombinant protein formulation
Vabysmo	Faricimab-svoa	Dual VEGF-A and Ang-2 pathway targeting	Distinct antibody formulation and delivery profile
Byooviz	Ranibizumab-nuna	Lucentis biosimilar	Biosimilar formulation and presentation
Cimerli	Ranibizumab-eqrn	Lucentis biosimilar with interchangeability positioning	Biosimilar formulation and presentation

Lucentis faces pressure from longer-interval products. That pressure increases the value of delivery innovation. A formulation improvement that does not reduce injection frequency may still compete through lower cost, lower waste, improved handling, or more reliable supply.

What commercial opportunities exist in Lucentis excipients?

Biosimilar formulation supply

Excipient manufacturers can target trehalose, histidine, histidine hydrochloride, and polysorbate 20 grades qualified for injectable biologics. Buyers will prioritize consistency, low bioburden, traceability, peroxide control, and regulatory documentation.

High-purity polysorbate systems

Polysorbate degradation is a recurring biologics-manufacturing concern. Suppliers with stronger control of oxidation, hydrolysis, fatty-acid distribution, and lot-to-lot variability can capture value from ranibizumab and other protein products.

Ready-to-use ophthalmic presentations

The prefilled syringe is commercially attractive because it can reduce preparation steps and minimize dosing errors. It also creates opportunities for:

• low-dead-space syringes;
• low-silicone or silicone-free systems;
• integrated needle assemblies;
• tamper-evident packaging;
• automated inspection;
• container-closure systems optimized for protein formulations.

Contract development and manufacturing

Ranibizumab biosimilars require cell culture, purification, aseptic filling, analytical characterization, and device integration. CDMOs with validated ophthalmic biologics capacity can compete for regional launches and private-label supply.

Sustained-delivery systems

Genentech's Susvimo platform demonstrates the commercial interest in reducing repeated intravitreal injections. Susvimo uses a surgically implanted port delivery system for ranibizumab and is a separate presentation from conventional Lucentis injections.[7] The opportunity is primarily device, reservoir, refill, and long-term stability IP rather than a simple excipient substitution.

What manufacturing and IP barriers affect ranibizumab opportunities?

Ranibizumab is a fragment-based biologic, and its manufacturing profile differs from that of full-length monoclonal antibodies. Key barriers include:

• control of aggregation and fragmentation;
• consistent Fab folding and disulfide formation;
• removal of host-cell proteins and DNA;
• control of charge variants;
• high-sensitivity potency assays;
• low-volume aseptic filling;
• particulate control;
• syringe and stopper compatibility;
• cold-chain management;
• comparative analytical packages for biosimilar approval.

The commercial barrier is therefore integrated. An excipient supplier with no biologics analytical support may be replaceable. A supplier that offers formulation development, stability studies, container compatibility, and regulatory documentation has a stronger position.

What generic entry risks exist for Lucentis?

Traditional generic entry is not the correct U.S. framework. Biosimilar entry is the relevant pathway. The main risks to Lucentis revenue are:

1. lower-priced Byooviz and Cimerli;
2. payer-mandated switching;
3. physician acceptance of interchangeable products;
4. hospital and retina-clinic purchasing contracts;
5. reduced use of originator prefilled syringes;
6. substitution by Eylea, Vabysmo, and other anti-VEGF therapies;
7. migration to longer-duration delivery systems.

The near-term commercial risk is highest in indications with established anti-VEGF treatment pathways and significant payer involvement. The originator can defend share through supply, contracting, device convenience, evidence generation, and differentiated delivery systems.

What is the revenue exposure for Lucentis stakeholders?

Lucentis revenue exposure is concentrated across four groups:

Stakeholder	Exposure
Originator sponsors	Price erosion, biosimilar substitution, and share migration to longer-interval therapies
Biosimilar manufacturers	Manufacturing cost, launch timing, contracting, and physician adoption
Excipient suppliers	Volume growth tied to biosimilar production and formulation changes
Device suppliers	Growth from prefilled syringes, low-waste systems, and sustained-delivery platforms

The largest excipient opportunity is unlikely to come from replacing the established Lucentis formula in the originator product. It is more likely to come from supplying biosimilar manufacturers, supporting next-generation ranibizumab presentations, and qualifying improved surfactant or container systems across multiple ophthalmic biologics.

Key Takeaways

• Lucentis uses ranibizumab with trehalose, histidine, histidine hydrochloride, polysorbate 20, and water for injection.
• The formulation is preservative-free, approximately pH 5.5, and supplied as a 10 mg/mL solution.
• Trehalose provides stabilization and contributes to tonicity; histidine controls pH; polysorbate 20 limits interfacial aggregation.
• U.S. competition is governed by the biosimilar pathway and Purple Book, not the conventional Orange Book generic framework.
• Byooviz and Cimerli are the principal U.S. ranibizumab biosimilars.
• The most valuable formulation IP is likely to involve stability, particle control, devices, container systems, dosing accuracy, and delivery technology.
• Commercial opportunities include high-purity excipients, prefilled syringes, low-dead-space devices, CDMO services, and sustained-delivery systems.
• Manufacturing barriers remain significant because ranibizumab requires tight control of aggregation, fragmentation, potency, particles, and aseptic filling.
• Lucentis is exposed to both biosimilar price erosion and therapeutic substitution by longer-interval anti-VEGF products.

FAQs

Can trehalose be replaced in a ranibizumab biosimilar?

Yes, but replacement would create a more complex comparability and regulatory program. The alternative must preserve stability, potency, particle control, ocular tolerability, and container compatibility.

Is Lucentis protected by Orange Book patents?

No. Lucentis is a biologic. FDA biologic reference-product and biosimilar information is maintained through the Purple Book rather than the Orange Book.

Which Lucentis excipient has the greatest manufacturing risk?

Polysorbate 20 often creates the greatest analytical and stability risk because oxidation and hydrolysis can generate degradation products and particles. Trehalose and histidine also require tight control but generally present a different risk profile.

Does a prefilled syringe create separate Lucentis patent value?

It can. Patent protection may cover the syringe, needle, silicone level, dose volume, container materials, filling method, or combination of the device with the ranibizumab formulation.

Is Susvimo an excipient-based version of Lucentis?

No. Susvimo is a separate ranibizumab delivery system using an implantable port and refill approach. Its commercial differentiation is primarily delivery technology, procedure, reservoir stability, and refill logistics.

References

1. U.S. Food and Drug Administration. (2024). Lucentis (ranibizumab injection) prescribing information. Genentech, Inc.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. U.S. Food and Drug Administration. (2021). FDA approves first biosimilar to treat certain eye conditions. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2022). FDA approves Cimerli, a biosimilar to Lucentis. https://www.fda.gov/

5. Samsung Bioepis. (2021). Byooviz ranibizumab-nuna product information and regulatory materials. Samsung Bioepis Co., Ltd.

6. Coherus BioSciences. (2022). Cimerli ranibizumab-eqrn product information. Coherus BioSciences, Inc.

7. U.S. Food and Drug Administration. (2023). Susvimo (ranibizumab injection) prescribing information. Genentech, Inc.